BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Neil Kumar

Charles Homcy

Frank McCormick

BridgeBio Pharma, Inc.

Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases.

Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.

BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

MyoKardia

Eidos Therapeutics

Blue Owl

CPP Investments

Qatar Investment Authority

Perceptive Advisors

Janus Fund

Viking Global Investors

Cormorant Capital

Kohlberg Kravis Roberts

Hercules Capital

AIG Investments

Sequoia Capital

Aisling Capital

BridgeBio

Our chief medical officer at BridgeBio Gene Therapy, 👤 Adam Shaywitz, M.D., Ph.D., will chair a panel today at the PMWC - Precision Medicine World Conference on novel clinical design approaches in rare diseases. Learn more about his session here: https://bit.ly/3vwZsdq

This week Dunni Odumosu, MS, vice president of regulatory affairs at BridgeBio Gene Therapy will lead a workshop at the Gene Therapy Regulatory Affairs Summit on the key learnings and best practices for optimizing regulatory interactions in the rapidly evolving field of gene therapy. Check out the agenda: https://bit.ly/3TWKJTs

In our latest episode of #OnRare we were privileged to speak with Effie Parks, a rare mom, a patient advocate, a podcaster, and host of “Once Upon a Gene.” Effie candidly shares her experience of being a new mom to a child living with a rare condition and her journey into the advocacy space. https://bit.ly/47H0S2q

We appreciate the partnership with the limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) advocacy groups and applaud their many achievements. We are excited to continue working on behalf of the LGMD community and to see what is next for 2024. Together We Are Stronger!

We are proud to share that the positive results from our Phase 3 ATTRibute-CM study have been published in the NEJM Group. We submitted our New Drug Application for acoramidis to the U.S. FDA in 2023 and intend to submit additional marketing authorization applications to regulatory bodies this year. Learn more: https://bit.ly/3TPN8iF

Thank you JPMorgan Chase & Co. for inviting us to present at the Annual Healthcare Conference! Our CEO and founder, Neil Kumar, Ph.D. shared our learnings across the ATTR-CM space since last year as well as provided updates on our late-stage programs, our research & early development candidates, and our priorities for 2024. #JPM24 Listen to our presentation here: https://bit.ly/3H3uL2b

To wrap up our 2023, our On Rare team recalled the wonderful, rare conversations we held with our extraordinary guests. Join us for a look back at 2023 and don’t forget to subscribe to learn more from our guests in 2024. https://bit.ly/3tL5rLd

BridgeBio founder & CEO Neil Kumar, Ph.D. is presenting at the J.P. Morgan 42nd Annual Healthcare Conference today at 8:15 a.m. PT. Join and learn about our goal to develop medicines for people with genetic diseases and cancers. Listen to the presentation here: https://bit.ly/3H3uL2b

We are on a mission to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases and cancers. Learn more about our upcoming presentation at the J.P. Morgan Annual Healthcare Conference, where we will discuss our milestones for the year. Read more: https://bit.ly/3H6969k

The U.S. FDA has cleared our investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct inhibitor of KRASG12C. We intend to begin enrollment of patients with KRASG12C mutant non-small cell lung cancer into our ONKORAS-101 trial, which is expected to begin in the first half of this year. Learn more: https://bit.ly/3H5JyJB

Metric
Company Name	BridgeBio Pharma, Inc.	Summit Therapeutics
Symbol	BBIO
MSH ID	COM:BRIDGEBIO	COM:SUMMITTHERAPEUTICS
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage		Post-IPO Equity
Employee Count	550
Website	bridgebio.com	summittherapeutics.com
LinkedIn	bridgebio
Founders

Metric
Market Cap	4.97B
Enterprise Value
Monthly Web Traffic		1.36K
Web Traffic Growth		-0.08
Valuation
Raised Capital		235M

Metric
Revenue	9.30M
Revenue (LTM)
Revenue (NTM)
Gross Profit	6.86M
EBITDA	-574.64M
Operating Income	-607.37M
Net Income	-643.20M
EPS	-0.00
Diluted EPS	-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99
Operating Profit Margin	-2.18
EBITDA Margin	-61.77
Net Profit Margin	-2.07
Return on Equity	0.53
Return on Assets	-0.57
Return on Capital Employed	-0.67

COM:BRIDGEBIO

BridgeBio Pharma, Inc.

Last Close

23.24

22/11 21:00

Market Cap

4.97B

Beta: -

Volume Today

2.05M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-8.25
P/B Ratio	-4.56
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	569.29
EV Multiple	-6.20

Metric
Days Sales Outstanding	200.15
Days Payables Outstanding	654.22
Days Inventory Outstanding	2.49K
Operating Cycle	2.55K
Cash Conversion Cycle	963.74
Asset Turnover	0.28

Metric
Operating Cash Flow	-527.72M
Free Cash Flow	-529.03M
Cash Flow to Debt
Operating Cash Flow/Sales	-1.89
Free Cash Flow Yield	-0.08

Metric
Cash & Equivalents	375.94M
Accounts Receivable	15.33M
Inventory	16.65M
Goodwill
Debt to Capitalization	4.51
Debt to Assets	2.66
Current Ratio	5.39
Quick Ratio	8.92

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	9.91
R&D to Revenue	44.37
SG&A to Revenue